These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34634502)

  • 1. Resistance to activated protein C and impaired TFPI activity in women with previous hormone-induced venous thromboembolism.
    Tchaikovski SN; Thomassen MCLGD; Stickeler E; Bremme K; Rosing J
    Thromb Res; 2021 Nov; 207():143-149. PubMed ID: 34634502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.
    Tanratana P; Ellery P; Westmark P; Mast AE; Sheehan JP
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):266-274. PubMed ID: 29097362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
    Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
    Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study.
    Winckers K; Siegerink B; Duckers C; Maurissen LF; Tans G; Castoldi E; Spronk HM; Ten Cate H; Algra A; Hackeng TM; Rosendaal FR
    J Thromb Haemost; 2011 Nov; 9(11):2243-50. PubMed ID: 21895962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
    Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
    J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin generation as an intermediate phenotype for venous thrombosis.
    Segers O; van Oerle Rv; ten Cate Ht; Rosing J; Castoldi E
    Thromb Haemost; 2010 Jan; 103(1):114-22. PubMed ID: 20062924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein S is a cofactor for tissue factor pathway inhibitor.
    Rosing J; Maurissen LF; Tchaikovski SN; Tans G; Hackeng TM
    Thromb Res; 2008; 122 Suppl 1():S60-3. PubMed ID: 18691502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral contraceptives on hemostasis and thrombosis.
    Rosing J; Tans G
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
    Tchaikovski SN; Thomassen MC; Costa SD; Peeters LL; Rosing J
    Thromb Haemost; 2011 Nov; 106(5):914-21. PubMed ID: 21979881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.
    Høibraaten E; Mowinckel MC; de Ronde H; Bertina RM; Sandset PM
    Br J Haematol; 2001 Nov; 115(2):415-20. PubMed ID: 11703344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives.
    Tchaikovski SN; Thomassen MC; Costa SD; Bremme K; Rosing J
    Thromb Res; 2014 Nov; 134(5):1032-7. PubMed ID: 25260941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of tissue factor pathway inhibitor in hormone-induced venous thromboembolism.
    Arafat A; Gennari P; Ignatov A; Tchaikovski S
    Blood Coagul Fibrinolysis; 2023 Jun; 34(4):233-238. PubMed ID: 37115963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased tissue factor-initiated prothrombin activation as a result of the Arg506 --> Gln mutation in factor VLEIDEN.
    van 't Veer C; Kalafatis M; Bertina RM; Simioni P; Mann KG
    J Biol Chem; 1997 Aug; 272(33):20721-9. PubMed ID: 9252393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
    Raps M; Helmerhorst FM; Fleischer K; Dahm AE; Rosendaal FR; Rosing J; Reitsma P; Sandset PM; van Vliet HA
    Thromb Haemost; 2013 Apr; 109(4):606-13. PubMed ID: 23407778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PO-24 - Determinants of thrombin generation in gynaecological malignancies.
    Norris LA; Martin FA; O'Toole SA; Saadeh FA; Gleeson N
    Thromb Res; 2016 Apr; 140 Suppl 1():S185. PubMed ID: 27161714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.
    Khialani D; Vasan S; Cushman M; Dahm AEA; Sandset PM; Rossouw J; van Hylckama Vlieg A
    J Thromb Haemost; 2021 Jul; 19(7):1729-1737. PubMed ID: 33774921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals.
    Maurissen LF; Castoldi E; Simioni P; Rosing J; Hackeng TM
    J Thromb Haemost; 2010 Apr; 8(4):750-8. PubMed ID: 20088940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.